Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 20/20 | 0.73 |
| ▸ | MAPK3 | P27361 | 3/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.73 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.73 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.73 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29357565 | 0.85 | SYK (1.00) | SYKMAPK3MAPK1KCNH2AURKB | |
| SCHEMBL2386517 | 0.85 | SYK (1.00) | SYKMAPK3MAPK1KCNH2AURKB | |
| SCHEMBL30240895 | 0.85 | SYK (1.00) | SYKMAPK3MAPK1KCNH2AURKB | |
| SCHEMBL2386521 | 0.85 | SYK (1.00) | SYKMAPK3MAPK1KCNH2AURKB | |
| SCHEMBL16195116 | 0.84 | SYK (1.00) | SYKMAPK3MAPK1KCNH2AURKB | |
| Hydrochloric Acid SCHEMBL29686198 | 0.84 | SYK (0.98) | SYKMAPK3MAPK1KCNH2AURKB | |
| SCHEMBL1353793 | 0.83 | SYK (1.00) | SYKMAPK3MAPK1KCNH2AURKB | |
| SCHEMBL1353792 | 0.83 | SYK (1.00) | SYKMAPK3MAPK1KCNH2AURKB | |
| SCHEMBL1353472 | 0.83 | SYK (1.00) | SYKMAPK3MAPK1KCNH2AURKB | |
| SCHEMBL1353471 | 0.83 | SYK (1.00) | SYKMAPK3MAPK1KCNH2AURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063058-B2 | Inhibitors of syk and JAK protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20100048567-A1 | Inhibitors of syk and JAK protein kinases | PORTOLA PHARMACEUTICALS INC. (US) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048567-A1 | Inhibitors of syk and JAK protein kinases | SYK, BTK, JAK1 | SYK 1/4885MAPK3 406/4885MAPK1 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.